Lysis of platelets releases the contents of the ␣-granules, which contain growth factors, including insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3). We investigated the mechanism by which IGF-I and IGFBP-3 appeared in the ␣-granules with a goal of modulating their levels in platelets to affect platelet functions.
extracellularly, endocytosis of the IGF-I:IGFBP-3 complex from the extracellular fluid by megakaryocytes was suggested. 2) We tested whether an IGF-I:IGFBP-3 complex comprised of human IGF-I and IGFBP-3 (recombinant 28.7 kDa) injected iv appeared in rat platelet ␣-granules. Hypophysectomized rats were injected iv with 5.24 mg of a 1:1 complex of IGF-I:IGFBP-3. After 24 h, platelet lysates were prepared and analyzed for IGFBP-3 by Western ligand blotting, and IGF-I was determined by RIA. Platelet lysates of the treated animals showed a prominent new band at approximately 28 kDa, whereas control rats were negative. In addition, the ␣-granule IGF-I concentration increased from 0.38 to 1.9 ng/1 ϫ 10 9 platelets. These results indicate that the IGF-I:IGFBP-3 complex is taken up by megakaryocytes and packaged into the ␣-granules of platelets and demonstrate how the contents of IGF-I and IGFBP-3 in platelets can be modulated by their plasma concentrations. As reverse transcription-PCR has shown that the IGF-I, but not the IGFBP-3, gene is expressed by megakaryocytes, there may be two mechanisms for directing IGF-I into the ␣-granules of platelets. (Endocrinology 139: 559 -565, 1998) I NSULIN-LIKE growth factor I (IGF-I) is an anabolic polypeptide that mediates the growth-promoting effects of GH (1) . The plasma and extracellular activity of IGFs are regulated by at least six different IGF-binding proteins (IGFBPs); the most abundant is IGFBP-3. IGF-I also has an important role in wound healing (2, 3) . Our laboratory has shown that IGF-I deficiency delays wound healing, IGF-I excess hastens tissue repair, and the IGF-I:IGFBP-3 complex is significantly more active than IGF-I alone (4) . Although the IGF-I complex acts at many points during the repair process, its action begins early, subsequent to platelet aggregation, which initiates discharge of the ␣-granules contents into the injured tissue. Both IGF-I and IGFBP-3 are released from the granules (5, 6) and are thought to act on macrophages, which orchestrate the cascade of reactions involved in tissue repair (2) .
The IGF-I and IGFBP-3 in platelets are important not only as early determinants of wound healing, but could be involved in other platelet functions, such as the maintenance of vascular integrity and atherogenesis (7) . Therefore, the ability to selectively modulate the platelet ␣-granule content of IGF-I and IGFBP-3 may assume considerable importance.
To accomplish this, the mechanism by which IGF-I and IGFBP-3 appear in the ␣-granules has to be established. ␣-Granule factors, such as epidermal growth factor, transforming growth factor-␤, and platelet-derived growth factor, are synthesized by megakaryocytes (8 -10) , whereas albumin, fibrinogen, and Igs are endocytosed by megakaryocytes and packaged into platelet ␣-granules. Therefore, we asked which of these mechanisms was responsible for IGF-I and IGFBP-3 appearance in the ␣-granules of platelets and whether we could modulate their amounts in platelets.
Materials and Methods Chemicals
Percoll, bovine fraction V, thrombin (T-7513), and Kodak Biomax MS film were purchased from Sigma Chemical Co. (St. Louis, MO). Ficoll 400 was purchased from Pharmacia Biotech (Piscataway, NJ). 1-Step-Platelet medium was obtained from Accurate Chemicals and Scientific Corp. (Westbury, NY). Ultraspec RNA is a product of Biotecx Laboratories (Houston, TX). Superscript preamplification kit and 10-and 100-bp DNA ladders were purchased from Life Technologies (Grand Island, NY). [ 125 I]IGF-I was purchased from Amersham Life Sciences (Arlington Heights, IL). An equimolar complex of recombinant human IGF-I and human IGFBP-3 (28.7 kDa) was provided by Celtrix Pharmaceuticals (Santa Clara, CA). Rabbit antirat IGF-I antiserum was a gift from Eli Lilly Research Laboratories (Indianapolis, IN). Animals, Scottsdale, PA), weighing 200 -250 g, were housed under a 12-h dark, 12-h light cycle and fed Purina rat chow (Ralston-Purina, St. Louis, MO) and water ad libitum.
Hypophysectomy was verified by significantly low plasma IGF-I levels, failure to gain weight, and significantly reduced levels of IGFBP-3 on a ligand blot. All laboratory procedures on animals were carried out in accordance with the NIH guidelines and the approval of the California Pacific Medical Center animal care committee (San Francisco, CA). Animals were anesthetized by inhalation of Metofane (Pitman-Moore, Mundelein, IL).
Isolation and purification of megakaryocytes
Rat megakaryocytes were isolated by a two-step procedure of Percoll density gradient centrifugation, followed by velocity sedimentation of the cells on a Ficoll medium (11) . Marrow cells were flushed from femurs of 250-g Long-Evans rats with CATCH medium (12) (1 mm adenosine, 2 mm theophyline, 0.76 g/liter sodium citrate, and 3.5% bovine fraction V, dissolved in Hanks' medium, pH 7.15). The cells were filtered through a nylon mesh, then layered on top of a Percoll step gradient (5%:10%: 20%:30%) in CATCH medium and centrifuged at 1000 ϫ g for 10 min at room temperature. The top megakaryocyte-containing layer was placed on top of a 2-4% continuous gradient of Ficoll in CATCH medium containing 5% FCS and centrifuged at 100 ϫ g for 5 min. The bottom 0.1 vol was removed and spun briefly to collect the megakaryocytes. A yield of 10 3 -10 4 megakaryocytes/rat was obtained, with up to 90% purity as assessed by microscopic characteristics.
Isolation and purification of platelets
Eight milliliters of rat blood were drawn from the inferior vena cava and collected in 50 U heparin and 1% acid citrate-dextrose solution. The blood was layered gently on top of 1-Step-Platelet medium at a ratio of 1:1 (vol/vol) and centrifuged at 350 ϫ g for 20 min at room temperature. The top platelet-rich layer was removed, diluted 3-fold with Tyrode buffer (50 mm HEPES, 30 mm dextrose, 4 mm KCl, 140 mm NaCl, 0.5 mm EDTA, and 0.35% bovine fraction V, pH 7.3), and centrifuged at 800 ϫ g for 20 min at room temperature. The pellet was washed in Tyrode buffer three times and used for RNA processing or thrombin activation. The platelets were counted and assessed for purity on a Coulter STKS-2A (Coulter Corp., Hialeah, FL).
Purification of messenger RNA (mRNA)
The mRNA from megakaryocytes, platelets, or rat embryo fibroblasts (purchased from the Tissue Culture Facility, University of CaliforniaSan Francisco) was isolated using the Ultraspec RNA reagent according to the manufacturer's recommendations. Megakaryocytes (1 ϫ 10 4 ), platelets (1 ϫ 10 9 ), or fibroblasts (1 ϫ 10 6 ; grown to confluence in DMEM in the presence of 5% FCS) were homogenized in 1 ml Ultraspec RNA reagent, extracted with 0.2 ml chloroform, then precipitated with isopropanol at a 1:2 ratio (vol/vol) and pelleted. After an ethanol wash, the final mRNA pellet was dried and dissolved in 25 l ribonuclease-free water.
RT-PCR amplification
RT was performed using the Superscript preamplification kit. The reaction was carried out in the presence of 10 U of Superscript II reverse transcriptase and 1-5 l mRNA sample [primed with oligo(deoxythymidine)] in a buffer of 0.5 mm NTP mix, 0.04 m dithiothreitol, 20 mm Tris-HCl (pH 8.4), 50 mm KCl, 2.5 mm MgCl 2 , and 0.1 g/l BSA for 50 min at 45 C. Ribonuclease H was added to the 20-l reaction mixture for 20 min at 37 C before termination by heating. PCR amplification was performed, using RT mixture (1-2 l), with sequence-specific primers against rat IGF-I (5Ј-ATCTCTTCTACCTGGCACTCTG-3Ј/5Ј-GAAG-CAACACTCATCCACAAT-3Ј), IGFBP-3 (5Ј-ACATCGCGTGACTGAT-TCC-3Ј/5Ј-CAGATGATTCAGTGTGTCCTCC-3Ј), and platelet factor-4 (PF-4; 5Ј-TGTGGTTGCTGTCACCAG-3Ј/5Ј-CTCCAGGAGTTTCTT-GATTATT-3Ј). The oligonucleotide pairs were designed to amplify a region that spanned an intron to remove the possibility of DNA contamination. PCR was carried out for 30 -50 cycles using TwinBlockCycler (Ericomp, San Diego, CA). Each cycle consisted of denaturation at 98 C (30 sec), annealing at 52-55 C (1 min), and extension at 72 C (1 min). Twenty microliters of a 50-l PCR mixture were electrophoresed on a 5% acrylamide gel and stained in ethidium bromide, and amplified products were visualized by UV illumination. Molecular sizes were estimated using a 100-bp DNA ladder.
Lysis of platelet ␣-granules with thrombin
Purified platelets (1 ϫ 10 9 ) in Tyrode buffer were spun down and resuspended in 200 l Dulbecco's PBS (pH 7.4) containing 0.1 g/liter CaCl 2 and 0.1 g/liter MgCl 2 . One unit of thrombin was added to the platelet suspension and incubated at 37 C for 5 min. The activated platelet suspension was spun down, and supernatant containing ␣-granule lysate was analyzed by Western ligand blotting or IGF-I RIA.
Western ligand blot analysis of IGFBPs
Western ligand blot analysis for IGFBPs was carried out using the method of Hossenlopp et al. (13) with significant modification. Three parts of sample were mixed with one part sample buffer and electophoresed under nonreducing conditions on a 12.5% SDS-polyacrylamide gel in Tris-HCl, pH 8.3. The separated proteins were blotted onto a nitrocellulose membrane, washed in 3% Nonidet P-40 Tris-buffered saline (TBS), then blocked in 1% bovine fraction V in TBS for 1 h. The nitrocellulose membrane was enclosed in a Seal-O-Meal bag, and 1 ϫ 10 6 cpm [
125 I]IGF-I in 10 ml blocking buffer was added. The bag was incubated on a rotary shaker for 2 h at room temperature. The membrane was subjected to three washes of TBS containing 0.1% Tween-20, followed by three washes in TBS alone. After drying, the membrane was exposed to Kodak Biomax MS film for 1-3 days at Ϫ80 C before development of the film.
Systemic administration of the human IGF-I:IGFBP-3 complex into a hypophysectomized rat
A 0.1-mol 1:1 complex of recombinant human IGF-I and 28.7-kDa nonglycosylated recombinant human IGFBP-3 in 1.0 ml phosphate buffer saline and 0.1% rat serum albumin was injected over 2 min by a 1-ml syringe into the jugular vein of an anesthetized hypophysectomized rat. Two hundred microliters of heparinized blood were taken at 1 h, and plasma was saved. At 24 h, the animal was exsanguinated, and blood was drawn from the inferior vena cava; 200 l were collected for plasma, and the rest was used for platelet processing.
RIA of IGF-I
IGF-I was separated from IGFBPs before RIA by the formic acidacetone extraction method (14) . The method was validated by obtaining the same results as those with chromatography on a 1 ϫ 110-cm Sephadex G-50 column equilibrated with 1 n acetic acid (the gold standard). One hundred microliters of platelet ␣-granule lysate or plasma were mixed with 50 l 8 n formic acid-0.05% Tween solution. After 5 min at room temperature, 350 l acetone were added to the mixture, which was placed at Ϫ20 C overnight to precipitate the IGFBPs. After centrifugation, the plasma supernatant was analyzed for IGF-I by RIA. The platelet lysate supernatant was dried completely by Speed-Vac (Savant Instruments, Farmingdale, NY), then reconstituted in assay buffer (50 mm basic sodium phosphate, 0.1% NaCl, 0.1% EDTA, 0.1% sodium azide, 0.02% protamine sulfate, and 0.05% Tween-20 adjusted to pH 7.5 with NaOH) before RIA. Antirat IGF-I antiserum was used at a final concentration of 1:60,000 in assay buffer. The RIA was performed at 4 C for 16 -20 h in polypropylene tubes, which contained 200 l standard (human IGF-I) or diluted sample in assay buffer, 200 l first antibody, and 200 l trace containing 10,000 cpm [
125 I]IGF-I. After incubation, 100 l of a 1:15 dilution of goat antirabbit ␥-globulin, 100 l of a 1:200 dilution of rabbit ␥-globulin, and 0.7 ml 9.14% polyethylene glycol 8000 (Sigma Chemical Co., St. Louis, MO) (pH 7.3) were added and mixed. After 15 min, the samples were centrifuged at 3000 ϫ g for 30 min at 4 C, and radioactive pellets were counted on a Berthold Gamma Counter LB 2104 (Wallac, Inc., Gaithersburg, MD). The nonspecific binding was less than 1%, and the specific binding of tracer was 43-50%. The interassay coefficient of variation was 2.6%.
Results

Expression of mRNAs for PF-4, IGF-I, and IGFBP-3 in rat megakaryocytes and platelets
The successful isolation of rat megakaryocyte mRNA was demonstrated by identification of transcripts of PF-4, a megakaryocyte-specific protein. The RT-PCR of the megakaryocyte mRNA with PF-4 primers resulted in a PCR product of ϳ236 bp (Fig 1A) . The PF-4 PCR product was confirmed as corresponding to PF-4 complementary DNA (cDNA) by restriction endonuclease digestion with BamHI, resulting in fragments of the predicted sizes, ϳ154 and ϳ82 bp ( Fig. 2A) . As expected, PF-4 transcripts were also present in platelets (Fig. 1A) .
Before testing megakaryocytes mRNA for IGF-I and IGFBP-3 transcripts, the primer sets for IGF-I and IGFBP-3 were tested on mRNA of rat fibroblasts and detected both. RT-PCR amplification with IGF-I primers resulted in a PCR product of ϳ198 bp, whereas IGFBP-3 primers yielded a PCR product of ϳ202 bp (Fig. 1B) . Both amplified cDNAs were validated by restriction enzyme analysis and corresponded to specific cDNAs of IGF-I and IGFBP-3 (data not shown). RT-PCR of rat megakaryocyte mRNA using IGF-I-specific primers resulted in a predicted IGF-I PCR product of ϳ198 bp. As megakaryocytes could be contaminated with leukocytes, platelet mRNA was analyzed and found to contain IGF-I transcripts (Fig. 1C) . The platelet IGF-I product was validated as corresponding to IGF-I cDNA by EaeI digestion, which produced the predicted DNA fragments of 155 and ϳ43 bp (Fig. 2B) . No IGFBP-3 transcript was detected in either megakaryocytes or platelets by the RT-PCR (Fig. 1D) .
Changes in platelet IGFBP-3 parallel serum changes in pregnant rats
Although IGF-I in ␣-granules could theoretically be explained by megakaryocyte synthesis, the presence of IGFBP-3 cannot. Therefore, the uptake of extracellular IGFBP-3 by megakaryocytes in the bone marrow was indirectly demonstrated by measuring IGFBP-3 incorporation into platelet ␣-granules. It is well established that serum IGFBP-3 decreases during late pregnancy in the rat due to a protease specific for the IGFBP-3 (15) . If IGFBP-3 were incorporated from extracellular fluid, the IGFBP-3 levels in platelets would be expected to mirror the changes in levels found in both serum and marrow fluid.
The Western ligand analysis of serum IGFBPs levels in rats during days 14, 15, 17, and 20 of pregnancy and days 1 and 3 postpartum was characterized by a major decrease in the 40-to 45-kDa IGFBP-3 starting on day 15 of pregnancy ( Fig.  3A) . From day 17 of pregnancy until delivery, the 40-to 45-kDa IGFBP-3 remained virtually undetectable in serum. On day 1 postpartum, a rapid recovery of the serum IGFBP-3 levels occurred (Fig. 3A) . Marrow fluid showed a similar IGFBP-3 profile during gestation and postpartum (Fig. 3B) . When the IGFBP-3 contents of ␣-granule of rat platelets were analyzed, their levels paralleled the changes found in both the serum and marrow fluid (Fig. 3C) . The pattern of platelet IGFBP-3 was characterized by a decrease in the amount on day 17 of pregnancy followed by its return to nonpregnancy levels on day 3 postpartum. The slight increase in IGFBP-3 in platelet lysate from days 14 to 15 of gestation was not reproduced in a repeat experiment; thus, we speculate that it might be caused by a minor variation in our platelet preparations. This particular ligand blot was presented because we felt it best reflected our overall results. Other IGFBPs of 24 and ϳ30 kDa were also noted in serum, marrow fluid, and platelet lysate. Interestingly, an increase in the ϳ24-and ϳ30-kDa IGFBPs in platelet lysate was observed at about the same time as IGFBP-3 declined in serum during late pregnancy.
Platelets coincubated with the IGF-I:IGFBP-3 complex in vitro failed to incorporate the complex (data not shown), supporting our hypothesis that in vivo megakaryocytes incorporated the IGFBP-3 and possibly other IGFBP forms as well. 
FIG. 2. Restriction digestion analysis of platelets' IGF-I and PF-4 RT-PCR products by EaeI and
Changes in platelet IGF-I in pregnant rats
Comparison of plasma IGF-I levels of nonpregnant rats with plasma IGF-I levels of day 20 pregnant and day 3 postpartum rats revealed a reduction in the IGF-I levels on day 20 in pregnant rats compared with the nonpregnant rat levels. On day 3 postpartum, the plasma IGF-I concentrations were restored to 85% of the nonpregnancy levels (Fig. 4A) . The IGF-I levels in the platelet lysate mirrored the changes in plasma IGF-I levels characterized by a lower amount of IGF-I on day 20 of pregnancy followed by their restoration to 80% of the nonpregnant levels on day 3 postpartum (Fig.  4B) . These changes are consistent with the previous finding of a decline in serum IGF-I during late gestation (15) .
Incorporation of an iv injected human IGF-I:IGFBP-3 complex into the ␣-granules of rat platelets
As the platelet lysate of hypophysectomized rats lacks a significant IGFBP in the 28 -30 kDa range, we tested whether an iv complex of a 28.7-kDa recombinant bacterial-derived human IGFBP-3 (rhIGFBP-3) and IGF-I would appear in platelet ␣-granules. The IGF-I:IGFBP-3 complex was injected into the animals, and plasma levels were monitored at 1 and 24 h by Western ligand analysis (Fig. 5, A-C) . The analysis revealed a prominent band characteristic of 28.7-kDa rhIGFBP-3 in the plasma 1 h after the injection (lane B) and minor bands before infusion of the complex (lane A) corresponding to rat IGFBPs. After 24 h, only 5% of the original 28.7-kDa rhIGFBP-3 remained in plasma (lane C). Western ligand analysis of platelet lysate of a rat that received the iv complex showed a new prominent band of 28.7 kDa (Fig. 5D) , whereas none of the 28.7-kDa protein was seen in platelet lysate of the control rat injected with saline. The results were additionally validated by immunoblotting with antihuman IGFBP-3 antiserum (data not shown). Other forms of IGFBPs were also present in the platelet lysate of hypophysectomized rats, albeit in reduced amounts. They were not visible on the Western ligand blot due to the much shorter film exposure time used to demonstrate the dominant 28.7-kDa IGFBP-3. The wash of platelets collected before their activation with thrombin contained only trace amounts of the 28.7-kDa IGFBP-3 (Fig. 5E) .
The systemic administration of the IGF-I:IGFBP-3 complex into the rats also resulted in an increase in both plasma and platelet IGF-I levels ( Table 1) . One hour postinfusion, plasma IGF-I levels increased 4-fold and reverted to preinfusion levels at 24 h. At 24 h, 4-fold higher IGF-I levels were detected in the platelet ␣-granule lysate of animals administered the iv complex.
Discussion
The current investigation describes the origins of IGF-I and IGFBP-3 stored in the ␣-granules of platelets. Our data show that IGFBP-3 in the ␣-granules is derived from the extracellular fluid in the bone marrow by megakaryocytic endocytosis. The IGF-I in ␣-granules may also be incorporated with the IGFBP-3 as a complex. As IGF-I transcripts were expressed in megakaryocytes, endogenous synthesis could also contribute to the IGF-I in platelet ␣-granules. In addition, this study demonstrates that the platelet ␣-granule contents of both IGF-I and IGFBP-3 can be modulated by altering their plasma levels.
mRNA phenotyping detected no IGFBP-3 transcripts in megakaryocytes; however, IGF-I transcripts were demonstrated. Although our megakaryocyte preparations could contain up to 10% leukocytes, these results were shown to reflect megakaryocyte functions by an analysis of platelet mRNA. Platelets can be purified essentially free of other blood cells and contain an appreciable amount of mRNA derived only from megakaryocytes. RT-PCR of platelet mRNA for the presence of transcripts of PF-4, a megakaryocyte-specific factor, and IGF-I gave the same results as those using megakaryocyte mRNA. No IGFBP-3 transcripts were found in platelets underscoring its absence in megakaryocytes.
As our data showed that megakaryocytes did not express IGFBP-3 mRNA, the IGFBP-3 present in the ␣-granules of platelets (6) had to be derived from another source. Direct uptake by platelets was first excluded by in vitro studies, leaving the most likely mechanism to be endocytosis of IGFBP-3 by megakaryocytes. It was previously shown that albumin, fibrinogen, and Igs were incorporated into the megakaryocytes from plasma via marrow fluid in this fashion (16) . If this mechanism pertains to IGFBP-3, then the platelet ␣-granule IGFBP-3 content should parallel the changes in serum IGFBP-3 levels. This was demonstrated by Western ligand analysis in pregnant rats, which shows a major decline in serum IGFBP-3 during late pregnancy due to an extracellular IGFBP-3-specific protease (15) . Indeed, the dramatic decrease in the 40-to 45-kDa IGFBP-3 occurring in the serum and marrow fluid of late pregnant rats was also reflected in the platelet ␣-granule IGFBP-3 content. In addition, the decline in IGFBP-3 levels in platelet ␣-granules was delayed during pregnancy in the rat. This is consistent with the time required for endocytosis of IGFBP-3 into megakaryocytes, packaging into ␣-granules, and platelet maturation. For the same reasons, a delay in the reappearance of IGFBP-3 levels in ␣-granules of platelets in postpartum rats was also observed on Western ligand analysis, as the half-life of platelets in rats is approximately 24 h. The changes in ␣-granule IGFBP-3 content are probably not caused by intracellular protease digestion, as the pregnancy-associated IGFBP-3 protease activity is generally accepted to be an extracellular phenomenon (17) . However, it is theoretically possible that the protease could be endocytosed and thus act intracellularly. This possibility will be explored in future studies. The increase in the 24-kDa IGFBP (presumably IGFBP-4) and ϳ30-kDa IGFBPs evident during late pregnancy in rats may be explained by decreased competition from IGFBP-3, possibly for a common carrier, or increased endocytosis to compensate for reduced levels of IGFBP-3 in the ␣-granules. However, we have not tested this concept. As other IGFBPs on a Western ligand blot of platelet lysate of pregnant rats also mirrored the forms of IGFBPs found in corresponding serum samples, the incorporation process may be common to other forms of IGFBPs.
To further test the endocytotic mechanism of megakaryocytes, a foreign IGFBP-3, rhIGFBP-3, complexed to human IGF-I was injected iv into hypophysectomized rats. The appearance of this human 28.7-kDa IGFBP-3 in rat ␣-granules 24 h later further established the endocytotic mechanism. The recombinant human IGFBP-3 in the platelet ␣-granule lysate was not due to carry-over of plasma recombinant human IGFBP-3, as the wash of the purified platelets contained only trace amounts of the IGFBP-3, most likely due to mechanical lysis. Hypophysectomized rats were used because their platelets contained very low IGF-I and IGFBP-3 levels, minimizing any possible competition for the endocytosis with the injected IGF-I:IGFBP-3 complex.
The iv injection of IGF-I:IGFBP-3 complex also caused higher amounts of IGF-I to appear in rat platelets. If the complex was endocytosed, this would explain the increase in IGF-I. The finding is consistent with the previous demonstration of parallel changes between platelet IGF-I levels and serum IGF-I levels during pregnancy and postpartum in rats. To what extent endogenous synthesis by megakaryocytes contributes to the ␣-granule content of IGF-I has yet to be shown. Although it is unlikely, it is theoretically possible that the endocytosed IGFBP-3 could The control animal was injected with saline. Plasma (200 l) was collected for IGF-I RIA 1 and 24 h postinjection of the complex. At 24 h, platelets were processed and treated with thrombin, and the lysate assayed for IGF-I. These results were confirmed in two other animals.
regulate the megakaryocyte synthesis of IGF-I. However, a previous finding of equimolar amounts of IGF-I and IGFBP-3 in ␣-granules of platelets (6) strengthens the hypothesis that ␣-granule IGF-I and IGFBP-3 were probably derived from extracellular fluid and housed in the ␣-granules as a complex.
IGF-I and IGFBP-3 are probably endocytosed into megakaryocytes as a complex. If they were endocytosed separately, the mode of transport of each would involve either pinocytosis or receptor-mediated uptake. Neither mechanism offers sufficient explanation for IGF-I, because pinocytosis of small polypeptides is unusual, and cell surface receptors target small polypeptides for lysosomal degradation. However, when one considers the IGF-I:IGFBP-3 complex, both mechanisms are possible.
IGFBPs are known to associate with cell membranes (18) , and IGFBP-3 has been found to react strongly with a receptor-like protein in Hs578T human breast cancer cells (19) . Thus, we speculate that the endocytosis of the IGF-I:IGFBP-3 complex is probably mediated by a IGFBP-3 carrier on the cell membrane. In fact, Li et al. (20) have recently reported the internalization and nuclear translocation of both IGF-I and IGFBP-3 in proliferating opossum kidney cells, suggesting that an endocytotic mechanism may operate in other cell systems. However, as the function and fate of the endocytosed IGF-I and IGFBP-3 in megakaryocytes are vastly different compared with those in other tissues, unique mechanisms may be involved in their uptake and packaging into ␣-granules. We have further demonstrated that the IGFBP-3 incorporated and stored in the platelet ␣-granules is functional.
The ability to modulate the concentrations of IGF-I and IGFBP-3 in ␣-granules of platelets has many therapeutic potentials. First, in wound healing, the IGF-I and IGFBP-3 levels in platelets are important because platelet contents are released immediately after trauma directly into the tissue, where additive and synergistic actions with other growth factors in ␣-granules, e.g. platelet-derived growth factor, epidermal growth factor, and transforming growth factor-␤, can promote tissue repair (21) . As there is a significant association of low plasma IGF-I and impaired wound healing, the list of conditions in which wound healing might benefit from increasing the ␣-granule content of IGF-I and IGFBP is impressive: malnutrition, glucocorticoid therapy, catabolic states, aging, chronic disease, GH deficiencies, and trauma (2) . Second, boosting the levels of IGF-I and IGFBP-3 in platelets before blood donation may help prolong the activity of platelets that is IGF dependent (see above). Third, platelets are important for preserving vascular integrity. As functional IGF-I receptors are present on endothelial cells (22) , increasing IGF-I levels in ␣-granules may improve vascular integrity and decrease the risk of bleeding in thrombocytopenia. Conversely, there may be benefits from lowering the ␣-granule content of IGF-I:IGFBP-3. Shepard has postulated that the atheromatous process is stimulated by deposition of IGF-I from plasma into the lesion (7) . Possibly a more significant source could be from the release of ␣-granule contents of IGF-I and IGFBP-3 (plus other growth factors) during platelet activation. Lowering ␣-granule IGF-I and IGFBP-3 contents could also be beneficial if IGF-I and IGFBP-3 were involved in the smooth muscle hypertrophy postangioplasty (23) (probably by acting synergistically with other growth factors). In the above-mentioned conditions, the role of IGFBP-3 may not be passive because of its ability to potentiate IGF-I actions in certain situations.
In summary, our findings demonstrate that megakaryocytes are capable of endocytosing both IGFBP-3 and IGF-I from the extracellular fluid and subsequently package them into platelet ␣-granules. This study also shows that platelet ␣-granule levels of IGF-I and IGFBP-3 are modulated by their plasma concentrations. As the IGF-I, but not the IGFBP-3, gene is expressed by megakaryocytes, there may be more than one mechanism for directing IGF-I into the ␣-granules of platelets. The IGF-I synthesized by the megakaryocytes may also be exported or act in a paracrine fashion. Further understanding of the underlying mechanisms involved in the endocytosis and incorporation of IGF-I and IGFBP-3 into platelet ␣-granule should permit various IGFs-dependent platelet functions to be influenced by manipulation of their ␣-granule contents.
